이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HUTCHMED (China) 과거 수익 실적

과거 기준 확인 0/6

HUTCHMED (China)은 연평균 9.5%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 2.3%의 비율로 수입이 감소했습니다. 매출은 연평균 31%의 비율로 증가했습니다.

주요 정보

9.5%

수익 성장률

13.5%

EPS 성장률

Pharmaceuticals 산업 성장	14.1%
매출 성장률	31.0%
자기자본 수익률	-5.6%
순이익	-6.9%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Sep 10

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

Aug 02

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

Jul 11

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

수익 및 비용 분석

HUTCHMED (China) 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

AIM:HCM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	611	-42	123	-49
31 Mar 24	724	29	128	-25
31 Dec 23	838	101	133	0
30 Sep 23	798	36	129	145
30 Jun 23	757	-29	125	145
31 Mar 23	592	-195	130	72
31 Dec 22	426	-361	136	0
30 Sep 22	414	-308	144	0
30 Jun 22	401	-255	152	0
31 Mar 22	376	-235	144	0
31 Dec 21	356	-195	127	0
30 Sep 21	317	-187	108	0
30 Jun 21	279	-178	89	0
31 Mar 21	258	-151	72	0
31 Dec 20	228	-126	61	0
30 Sep 20	221	-117	55	0
30 Jun 20	209	-110	54	0
31 Mar 20	204	-102	51	0
31 Dec 19	205	-106	53	0
30 Sep 19	205	-93	55	0
30 Jun 19	214	-87	51	0
31 Mar 19	214	-83	51	0
31 Dec 18	214	-75	49	0
30 Sep 18	218	-72	46	0
30 Jun 18	217	-61	46	0
31 Mar 18	230	-39	44	0
31 Dec 17	241	-27	43	0
30 Sep 17	240	-7	43	0
30 Jun 17	238	13	42	0
31 Mar 17	227	12	41	0
31 Dec 16	216	12	40	0
30 Sep 16	200	38	51	0
30 Jun 16	200	-8	37	0
31 Mar 16	189	-22	34	0
31 Dec 15	178	-35	30	0
30 Sep 15	168	-80	12	0
30 Jun 15	139	-66	15	0
31 Mar 15	113	-50	16	0
31 Dec 14	87	-35	17	0
30 Sep 14	72	-20	18	0
30 Jun 14	59	7	24	0
31 Mar 14	52	8	24	0
31 Dec 13	37	26	16	0
30 Sep 13	38	10	26	0

양질의 수익: HCM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: HCM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: HCM 은(는) 수익성이 없지만 지난 5년 동안 연간 9.5% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 HCM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: HCM 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 1.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: HCM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -5.61% )을 갖습니다.

HUTCHMED (China) 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

Recent updates

Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt?

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Investor sentiment improves as stock rises 16%

Consensus EPS estimates upgraded to US$0.11 loss

HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

CFO & Executive Director recently sold UK£2.4m worth of stock